Literature DB >> 26325263

Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis.

R Matthew Chico1, Jorge Cano1, Cono Ariti1,2, Timothy J Collier1, Daniel Chandramohan1, Cally Roper1, Brian Greenwood1.   

Abstract

OBJECTIVES: To estimate where intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) could be withdrawn as an intervention due to declining malaria transmission intensity, or due to increasing prevalence of the Plasmodium falciparum dihydropteroate synthetase resistance mutation at codon 581G.
METHODS: We conducted a systematic review and meta-analysis of protection against the incidence of low birth weight (LBW) conferred by ≥2 doses of IPTp-SP. We matched these outcomes to a proxy measure of malaria incidence in women of the same studies, applied meta-regression models to these data and conducted sensitivity analysis of the 581G mutation.
RESULTS: Variation in the protective effect of IPTp-SP against LBW could not be explained by malaria transmission intensity. Among primi- and secundigravidae, IPTp-SP protected against LBW where 581G was ≤10.1% [odds ratio (OR): 0.49; 95% confidence intervals (CI): 0.29, 0.81; P = <0.01] and 581G was >10.1% (OR = 0.73; 95% CI: 0.29, 1.81; P = 0.03). Random-effects models among multigravidae showed that IPTp-SP protects against LBW where 581G was ≤10.1% (OR = 0.56; 95% CI: 0.37, 0.86; P = 0.07), a finding of borderline statistical significance. No evidence of protection against LBW was observed where 581G was >10.1% (OR = 0.96; 95% CI: 0.70, 1.34; P = 0.47).
CONCLUSION: There appears to be a prevalence of 581G above which IPTp-SP no longer protects against LBW. Pregnancy studies are urgently needed where 581G is >10.1% to define the specific prevalence threshold where new strategies should be deployed.
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  drug resistance; malaria; pregnancy; sub-Saharan; sulphadoxine-pyrimethamine; transmission

Mesh:

Substances:

Year:  2015        PMID: 26325263     DOI: 10.1111/tmi.12595

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  27 in total

1.  Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.

Authors:  Meghna Desai; Julie Gutman; Anne L'lanziva; Kephas Otieno; Elizabeth Juma; Simon Kariuki; Peter Ouma; Vincent Were; Kayla Laserson; Abraham Katana; John Williamson; Feiko O ter Kuile
Journal:  Lancet       Date:  2015-09-28       Impact factor: 79.321

2.  Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers.

Authors:  Victor S Koko; Marian Warsame; Benjamin Vonhm; Moses K Jeuronlon; Didier Menard; Laurence Ma; Fahn Taweh; Lekilay Tehmeh; Paye Nyansaiye; Oliver J Pratt; Sei Parwon; Patrick Kamara; Magnus Asinya; Aaron Kollie; Pascal Ringwald
Journal:  Malar J       Date:  2022-04-27       Impact factor: 3.469

Review 3.  The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review.

Authors:  Renée J Burger; Benjamin J Visser; Martin P Grobusch; Michèle van Vugt
Journal:  Malar J       Date:  2016-02-18       Impact factor: 2.979

4.  User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya.

Authors:  Jenny Hill; Jenna Hoyt; Florence Achieng; Peter Ouma; Anne L'lanziva; Simon Kariuki; Meghna Desai; Jayne Webster
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

5.  Burden of Placental Malaria among Pregnant Women Who Use or Do Not Use Intermittent Preventive Treatment at Mulago Hospital, Kampala.

Authors:  Charles Okot Odongo; Michael Odida; Henry Wabinga; Celestino Obua; Josaphat Byamugisha
Journal:  Malar Res Treat       Date:  2016-12-13

6.  Profile of molecular mutations in pfdhfr, pfdhps, pfmdr1, and pfcrt genes of Plasmodium falciparum related to resistance to different anti-malarial drugs in the Bata District (Equatorial Guinea).

Authors:  Pedro Berzosa; Andrés Esteban-Cantos; Luz García; Vicenta González; Marisa Navarro; Taiomara Fernández; María Romay-Barja; Zaida Herrador; José Miguel Rubio; Policarpo Ncogo; María Santana-Morales; Basilio Valladares; Matilde Riloha; Agustín Benito
Journal:  Malar J       Date:  2017-01-13       Impact factor: 2.979

7.  Evaluation of Malaria Screening during Pregnancy with Rapid Diagnostic Tests Performed by Community Health Workers in Burkina Faso.

Authors:  Esmée Ruizendaal; Henk D F H Schallig; Susana Scott; Maminata Traore-Coulibaly; John Bradley; Palpouguini Lompo; Hamtandi M Natama; Ousmane Traore; Innocent Valea; Susan Dierickx; Koiné M Drabo; Franco Pagnoni; Umberto d' Alessandro; Halidou Tinto; Petra F Mens
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

8.  Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda.

Authors:  Vera Braun; Eva Rempis; Alexandra Schnack; Sarah Decker; John Rubaihayo; Nazarius Mbona Tumwesigye; Stefanie Theuring; Gundel Harms; Priscilla Busingye; Frank P Mockenhaupt
Journal:  Malar J       Date:  2015-09-26       Impact factor: 2.979

9.  Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania.

Authors:  Reginald A Kavishe; Robert D Kaaya; Sidsel Nag; Camilla Krogsgaard; Jakob Ginsbak Notland; Adellaida A Kavishe; Deus Ishengoma; Cally Roper; Michael Alifrangis
Journal:  Malar J       Date:  2016-06-23       Impact factor: 2.979

10.  Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial.

Authors:  Mwayiwawo Madanitsa; Linda Kalilani; Victor Mwapasa; Anna M van Eijk; Carole Khairallah; Doreen Ali; Cheryl Pace; James Smedley; Kyaw-Lay Thwai; Brandt Levitt; Duolao Wang; Arthur Kang'ombe; Brian Faragher; Steve M Taylor; Steve Meshnick; Feiko O Ter Kuile
Journal:  PLoS Med       Date:  2016-09-13       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.